韩国红人参提取物粉减轻了2型糖尿病小鼠的禁食和食后高血糖症
Min-Jeong Jo1, Sun Jin Hwang1, Han-Ol Kwon2
1Department of Histology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea.
Journal of medicinal food
|September 12, 2024
概括
红人参提取物粉 (RGEP) 在2型糖尿病 (T2DM) 的小鼠模型中有效改善了血糖控制和胰岛素敏感性. RGEP显示出作为治疗糖尿病并发症的补充疗法的潜力.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 代谢性疾病 研究 研究 研究
- 自然产品治疗药物 自然产品治疗药物
背景情况:
- 2型糖尿病 (T2DM) 的特点是胰岛素抵抗和高血糖,导致严重的并发症.
- 帕纳克斯人参 迈耶的红人参提取物粉末 (RGEP) 已显示出糖尿病管理的潜力,但其在T2DM中的有效性需要进一步研究.
研究的目的:
- 在T2DM小鼠模型中评估RGEP的治疗有效性.
- 评估RGEP对葡萄糖调节,胰岛素敏感性和相关基因表达的影响.
主要方法:
- db/db小鼠被口服RGEP (50-400 mg/kg) 或甲胺治疗了9周.
- 测量了代谢参数,包括禁食血糖,口服葡萄糖耐受性测试 (OGTT) 和胰岛素耐受性测试 (ITT).
- 分析了参与肝脏葡萄糖生成,胰岛素敏感性和线粒体能量代谢的mRNA基因表达.
主要成果:
- 正如OGTT和ITT所示,RGEP在所有剂量中显著降低了禁食血糖,并在400mg/kg时改善了血糖控制.
- 观察到血清葡萄糖,HbA1c和HOMA-IR值的剂量依赖性降低,表明胰岛素耐药性得到改善.
- RGEP调节了葡萄糖生成,胰岛素信号和能量代谢途径中的关键基因的表达,包括GLP-1的上调.
结论:
- 作为2型糖尿病的有效补充疗法,RGEP显示出显著的潜力.
- RGEP 改善了与葡萄糖平衡和胰岛素敏感性相关的代谢参数和基因表达,这表明它在治疗糖尿病并发症方面具有有效性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183


